

ALASKA MEDICAID  
Prior Authorization Criteria

**Dojolvi™  
(triheptanoin)**

**FDA INDICATIONS AND USAGE**<sup>1,2</sup>

Dojolvi™ is a medium-chain triglyceride indicated as a source of calories and fatty acids for the treatment of pediatric and adult patients with molecularly confirmed long-chain fatty acid oxidation disorders (LC-FAOD).

**APPROVAL CRITERIA**<sup>1,2</sup>

1. Patient has a molecularly confirmed diagnosis of a long-chain fatty acid oxidation disorder based on at least TWO of the following (a, b, or c):
  - a. Disease-specific elevations of acylcarnitines on a newborn blood spot or in plasma; **OR**
  - b. Enzyme activity assay (in cultured fibroblasts or lymphocytes) below the lower limit of the normal reference range for the reporting laboratory; **OR**
  - c. Genetic testing demonstrating pathogenic mutation in a gene associated with long-chain fatty acid oxidation disorders **AND**;
2. Is being prescribed by or in consultation with an endocrinologist or metabolic disease specialist **AND**;
3. The prescriber has submitted the patient's weight and total prescribed daily caloric intake **AND**;
4. The dose does not to exceed 35% of Daily Caloric Intake.

**DENIAL CRITERIA**<sup>1</sup>

1. Failure to meet approval criteria **OR**;
2. Patient is concurrently using another medium chain triglyceride product.

**CAUTIONS**<sup>1</sup>

- Avoid co-administration of Pancreatic Lipase Inhibitors due to potential for reduced clinical effect.

**DURATION OF APPROVAL**

- Initial Approval: up to 3 months
- Reauthorization Approval: up to 12 months

**QUANTITY LIMIT**

Dojolvi™ Criteria  
Version: 1  
Original: 10/08/20  
Approval: 11/20/20  
Effective: 1/11/21

ALASKA MEDICAID  
Prior Authorization Criteria

- 30 days – dose does not exceed 35% of the patient’s caloric intake

**REFERENCES / FOOTNOTES:**

1. Dojolvi [package insert]. Novato, CA Ultragenyx Pharmaceutical Inc. June 2020.  
<https://www.ultragenyx.com/medicines/dojolvi-full-prescribing-information/>. Accessed on 10/08/2020
2. FDA Approves Dojolvi (triheptanoin) for the Treatment of Long-Chain Fatty Acid Oxidation Disorders, <https://www.drugs.com/newdrugs/fda-approves-dojolvi-triheptanoin-long-chain-fatty-acid-oxidation-disorders-5283.html>. Accessed 10/08/2020